SOLICITATION NOTICE
A -- Vaccine Component Production
- Notice Date
- 9/22/2008
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- W23MYC8178N024
- Response Due
- 9/26/2008
- Archive Date
- 11/25/2008
- Point of Contact
- Pamela E. Nevels, 301-619-8802<br />
- Small Business Set-Aside
- N/A
- Description
- The United States Army Medical Research Acquisition Activity (USAMRAA) intends to negotiate a contract on an other than full and open competition basis with GenPhar Inc, 871 Lowcountry Boulevard, Mount Pleasant SC. The specific objective of this procurement action is to procure sufficient quantities of filovirus vaccine components, EBO7 and M8, to complete the evaluation process under 1.1C0001_07_RD_B. Additionally, we would like to have components developed for Sudan ebolavirus (SEBOV) and Marburgvirus (MARV) that will produce antigen for ELISAs and we would want sufficient quantities of GP antigen (ZEBOV, SEBOV and MARV) produced for evaluation in a validated ELISA down-selection The USAMRIID has been engaged in the research and development of a multivalent filovirus vaccine with GenPhar, Inc. for over seven and a half years. Much of this collaboration was done through a Cooperative Agreement which had a performance period end date of 31 May 2007. We are now in a final period of evaluation of this multivalent filovirus vaccine and need additional vaccine doses of the same type and consistency to complete our studies. Another contractor would be unable to provide USAMRIID will equivalent product. GenPhar has also produced other components that for evaluation. One of these components, EBO3, has shown the ability to produce Zaire ebolavirus (ZEBOV) glycoprotein (GP) antigen in sufficient quality and quantity to have value to USAMRIID in the development of validated ELISAs for filoviruses. Because of this experience and proven ability to deliver a product that meets the governments needs, GenPhar is the optimal source for the development of these reagents. This is not a request for competitive proposals. Any responses to this synopsis must be provided in writing and include qualifications, experience, past performance and proposed costs to provide this type of services. All responses will be considered be reviewed and considered for future requirements of this type. Your responses should be provided by 5:00 pm Eastern Standard time on Friday September 26, 2008. Provide responses to pamela.nevels@amedd.army.mil.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=18cf114b281d5134e6232843c9306a6c&tab=core&_cview=1)
- Place of Performance
- Address: US Army Medical Research Acquisition Activity ATTN: MCMR-AAA, 820 Chandler Street Frederick MD<br />
- Zip Code: 21702-5014<br />
- Zip Code: 21702-5014<br />
- Record
- SN01677660-W 20080924/080922215707-18cf114b281d5134e6232843c9306a6c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |